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Abstract
Background: The PAST-BP trial found that using a lower systolic blood pressure target (<130mmHg or lower versus
<140mmHg) in a primary care population with prevalent cerebrovascular disease was associated with a small additional
reduction in blood pressure (2.9mmHg).
Objectives: To determine the cost effectiveness of an intensive systolic blood pressure target (<130mmHg or lower)
compared with a standard target (<140mmHg) in people with a history of stroke or transient ischaemic attack on
general practice stroke/transient ischaemic attack registers in England.
Methods: A Markov model with a one-year time cycle and a 30-year time horizon was used to estimate the cost per
quality-adjusted life year of an intensive target versus a standard target. Individual patient level data were used from the
PAST-BP trial with regard to change in blood pressure and numbers of primary care consultations over a 12-month
period. Published sources were used to estimate life expectancy and risks of cardiovascular events and their associated
costs and utilities.
Results: In the base-case results, aiming for an intensive blood pressure target was dominant, with the incremental
lifetime costs being £169 lower per patient than for the standard blood pressure target with a 0.08 quality-adjusted life
year gain. This was robust to sensitivity analyses, unless intensive blood pressure lowering reduced quality of life by 2% or
more.
Conclusion: Aiming for a systolic blood pressure target of <130mmHg or lower is cost effective in people who have
had a stroke/transient ischaemic attack in the community, but it is difficult to separate out the impact of the lower target
from the impact of more active management of blood pressure.
Keywords
Hypertension, stroke, transient ischaemic attack, blood pressure target, cost effectiveness, decision model, decision
analysis
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Background
Stroke is a major cause of morbidity and mortality in
the UK. There are approximately 110,000 strokes per
year in England and around 300,000 people living with
moderate to severe disabilities as a result of stroke.1
After a ﬁrst stroke, patients are at high risk of a recur-
rent event: for every 1000 ﬁrst strokes, 240 will have
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a recurrent cardiovascular disease event within ﬁve
years of the ﬁrst episode, of which 180 would be a
stroke and 29 of these would be fatal.2 In 2008–2009,
the direct care cost of stroke was £3 billion annually,
within a wider economic cost of about £8 billion.
Without preventive action, there is likely to be an
increase in strokes as the population ages.1 Therefore,
secondary prevention has a major potential role to play
in reducing both morbidity and costs of stroke care.
There is controversy over how intensively to lower
blood pressure (BP) in people who have had a stroke,
with diﬀerent international guidelines recommending
diﬀerent target BPs,3,4 and uncertainty over the applic-
ability of the current evidence base for BP reduction
after stroke to people with a history of transient ischae-
mic attack (TIA) or stroke in community popula-
tions.5,6 A systematic review of the eﬀect of intensive
BP lowering in populations including those with a his-
tory of stroke found that more intensive BP lowering
does lead to reduced risk of major cardiovascular
events,6 and the recent SPRINT trial, albeit in a popu-
lation without a history of stroke, found that intensive
BP lowering reduced major cardiovascular events and
all-cause mortality.7 Therefore, there is renewed inter-
est in strategies to lower BP intensively in high-risk
populations, such as those with a history of stroke or
TIA. The Prevention AfTer Stroke – Blood Pressure
(PAST-BP) randomised controlled trial compared the
impact of an intensive systolic blood pressure (SBP)
target (<130mmHg or 10mmHg reduction from base-
line if this was <140mmHg) with a standard target
(<140mmHg) in people with a history of stroke or
TIA recruited from primary care.8 The trial involved
active management in all patients, and found that this
led to important reductions in BP in both arms.9 The
more intensive target was associated with only a small
additional reduction in BP (2.9mmHg), which raises
the question as to whether such an intensive target is
cost eﬀective.
Here, we report the results of a model-based cost-uti-
lity analysis, which extrapolates the results of the PAST-
BP trial9 to estimate the long-term cost eﬀectiveness of
intensive BP lowering targets after stroke/TIA in a pri-
mary care population, compared to a standard target.
Methods
A Markov model was constructed to estimate the long-
term cost eﬀectiveness, in terms of the cost per quality-
adjusted life year (QALY) gained, of an intensive target
strategy versus a standard target strategy for BP low-
ering in people with a history of stroke or TIA. The
model was developed using TreeAge Pro Suite 2012
software (TreeAge Software Inc., Williamstown, MA,
USA). The analysis was conducted from a UK
National Health Service (NHS) and personal social ser-
vices perspective.10
The model had a time cycle of one year with a 30-
year time horizon (i.e. lifetime). The base-case analysis
considered a cohort similar to that recruited to the
PAST-BP trial (aged 70 years, 41% female). Baseline
characteristics for important potential confounders
were similar in both arms.9 Movements between
model health states were deﬁned by transition probabil-
ities, which represented the risk of experiencing an
event within a year time cycle. Long-term costs and
health outcomes were assessed by attaching estimates
of costs and utilities to the model health states. QALYs
were calculated by multiplying life expectancy by the
health state utility. Cost eﬀectiveness was expressed as
cost per additional QALY gained. The structure of the
Markov model is shown in Figure 1.
Individual patient level data were used from the
PAST-BP trial9 supplemented by parameter estimates
from published studies (Table 1). In the PAST-BP trial9
participants were recruited from stroke/TIA registers
in English general practices during 2009–2011 and
were randomly assigned to an intensive BP target
(<130mmHg or a 10mmHg reduction if baseline pres-
sure was <140mmHg) or a standard SBP target
(<140mmHg). Over one year, mean SBP dropped
by 16.1mmHg in the intensive target arm and by
12.8mmHg in the standard arm (adjusted diﬀerence
between groups 2.9mmHg, P¼ 0.03). For extrapola-
tion beyond one year, we assumed that this diﬀerence
in BP was maintained.
Model structure and inputs
The cohort started in the initial health state ‘previous
stroke/TIA’, and a patient could remain in the ‘previous
stroke/TIA’ health state if they did not have a recurrent
event or died. If a cardiovascular event or death occurred
the patient moved to one of four possible health states:
new stroke, myocardial infarction (MI), unstable angina
(UA), or dead (see Figure 1). Life tables were used to
determine overall mortality dependent on age and
gender, adjusted by cardiovascular disease mortality.11
Death was attributed to either stroke, MI or other
causes. After a cardiovascular event, individuals could
survive from the event or die, with death from an event
occurring within a year. Individuals who survived a car-
diovascular event moved to the chronic health state for
that event, in which annual costs were incurred and qual-
ity of life was lower than in the ‘previous stroke/TIA’
state (Table 1). Individuals in a chronic health state
were assumed to remain in that state for the rest of
their lives unless they died from other causes.
Annual transition probabilities determining the risk
of a cardiovascular event were based on the results of
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the PROGRESS trial.12 Age-related risk reductions for
coronary heart disease (CHD) and stroke associated with
subsequent reductions in SBP observed in the PAST-BP
trial were obtained from Law et al. (Table 1).13 The risk
reduction for CHD was applied to both MI and UA.
This approach has previously been used by other studies
to convert a decrease in SBP to reductions in CHD and
stroke risk.14,15 The probability of each cardiovascular
event occurring, the risks of dying from stroke or MI
and the increased risk of death once in a chronic health
state incorporated in the model are shown in Table 1.
Outcomes and costs were discounted at the standard
annual rate of 3.5%.10
Resource use and costs
Costs are reported in UK pounds at 2011–2012 unit
prices, and are discounted at 3.5% per annum.10
Costs were derived from a combination of standard
unit costs, NHS reference costs and previously pub-
lished literature and were adjusted using the Hospital
and Community Health Service index to the 2011/2012
price year.16 Resource use and costs per patient were
obtained from the PAST-BP trial and applied to the ini-
tial health state in the model.9 Costs for acute and
chronic states were obtained from published sources.17–20
Costs considered over the lifetime of the model included
the cost of antihypertensive drugs, consultation costs and
subsequent cardiovascular events (Table 1).
Utility values
The primary outcome measure was QALYs (Table 1).
The utility value for the starting ‘previous stroke/TIA’
health state in the model was obtained from the
PAST-BP trial using the overall mean EQ-5D score at
baseline. The EQ-5D is a widely used generic instru-
ment that has been validated in many patient popula-
tions, and is recommended by the National Institute
for Health and Care Excellence (NICE).10 This was
adjusted for age group using weights calculated from
Ara and Brazier,21 which allowed a reduction in quality
of life with increasing age to be incorporated in
the model. Acute events were assumed to happen six
months into a one-year cycle. Individuals stayed in that
acute state for six months before moving into a chronic
health state. Utilities for the acute state were applied
mid-way through the one-year cycle and those for the
chronic state at the start of the next cycle following an
acute event. Future health state utilities were estimated
by multiplying the starting quality of life with that of
the new health state. In the base-case analysis it was
assumed that diﬀerent intensities of BP management
had no eﬀect on quality of life.22
Analysis
An incremental cost-utility analysis was undertaken.
Probabilistic sensitivity analysis was based on 10,000
Intensive blood
pressure lowering
Usual care
Previous stroke/TIA
Post stroke
Post MI
Other death
Post unstable angina
Event free
Stroke
Unstable angina (UA)
Other death
Survive
Survive
Survive
Survive
Survive
Die
Die
Die
Die
Die
Myocardial infarction (MI)
Figure 1. Markov model.
Note: The Markov model in this figure is only being displayed for the ‘intensive blood pressure lowering’ strategy. The standard target
strategy is identical. Similarly, the model is identical at every node ending with green circles. Final outcomes (shown as red triangles)
are survival and death.
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Table 1. Model parameters.
Parameter Value Distribution Source
Reduction in systolic blood pressure at 12 months (mmHg)
Intensive BP lowering 16.1
PAST-BP trial9Standard target 12.8
12 Months’ difference
between groups (95% CI)
–2.9 (–5.7, 0.2)
Annual event probabilities
Stroke
60–69 years old 0.0348 PROGRESS & NICE,
Lipid Modification Guidelines12,1870–79 years old 0.0589
80–89 years old 0.0713
MI and UA
60–69 years old 0.0139 PROGRESS & NICE,
Lipid Modification Guidelines12,1870–79 years old 0.0232
80–89 years old 0.0232
Age-related relative risks at 12 months for intensive and standard BP loweringa
MI and UA – intensive BP lowering
60–69 years old 0.62 [0.59, 0.65]
PAST-BP trial & Law et al.9,1370–79 years old 0.68 [0.63, 0.70]
80–89 years old 0.74 [0.69, 0.77]
Stroke – intensive BP lowering
60–69 years old 0.52 [0.47, 0.56]
PAST-BP trial & Law et al.9,1370–79 years old 0.58 [0.54, 0.63]
80–89 years old 0.74 [0.68, 0.78]
MI and UA – standard target
60–69 years old 0.68 [0.65, 0.70]
PAST-BP trial & Law et al.9,1370–79 years old 0.72 [0.69, 0.75]
80–89 years old 0.78 [0.74, 0.81]
Stroke – standard target
60–69 years old 0.59 [0.55, 0.63]
PAST-BP trial & Law et al.9,1370–79 years old 0.65 [0.61, 0.68]
80–89 years old 0.78 [0.73, 0.82]
Utilities for the initial health state
Intensive BP lowering and standard target
60–69 years old 0.7241 Beta
PAST-BP trial970–79 years old 0.6631 Beta
80–89 years old 0.6362 Beta
Utilities for acute diseaseb
UA 0.77 Beta NICE, Lipid
Modification Guidelines18MI 0.76 Beta
Stroke 0.63 Beta
Dead 0.00 By definition
Utilities for long-term (chronic) diseaseb
UA 0.88 Beta NICE, Lipid
Modification Guidelines18MI 0.88 Beta
Stroke 0.63 Beta
Probability of death from an event
Fatal stroke 0.23 Beta Bamford et al.29
Fatal MI
60–69 years old 0.23 ONS, Deaths Registry 2011 &
Kerr et al.11,3070–79 years old 0.39
80–89 years old 0.52
(continued)
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Monte Carlo simulations. A gamma distribution
was ﬁtted to the costs obtained from the PAST-BP
trial. Beta distributions were used to model the prob-
ability of dying from any of the cardiovascular events
as well as the uncertainty around the utility values.
A cost-eﬀectiveness plane23 and a cost-eﬀectiveness
acceptability curve (CEAC) were constructed, the latter
to depict the probability of intensive BP lowering being
more cost eﬀective compared to standard target at dif-
ferent cost per QALY willingness-to-pay thresholds.
Uncertainty in the results of the model was assessed
through sensitivity analyses. These involved: varying
the time horizon for the model; changing costs of dis-
ease and the initial cost for the intensive BP lowering
arm by 30%; varying the eﬀect size in the intensive BP
lowering arm according to the 95% conﬁdence interval
of the BP reduction diﬀerence achieved at 12 months;
incorporating a quality of life decrement due to anti-
hypertensive medication by reducing utility values
(multiplicatively) for the initial health state in the inten-
sive BP lowering arm by up to 10%.21
Results
The base-case lifetime costs and QALYs are presented
in Table 2. Compared to a standard BP target of
140mmHg SBP, intensive BP lowering was in a pos-
ition of dominance, being cheaper and more eﬀective.
Table 1. Continued
Parameter Value Distribution Source
Annual cost of consultation per patient (UK£) – intensive BP lowering
GP consultations 86
PAST-BP trial & Curtis9,16PN consultations 35
Annual cost of consultation per patient (UK£) – standard target
GP consultations 50
PAST-BP trial & Curtis9,16PN consultations 29
Average cost of hypertensive drugs per patient £per yearc
Intensive BP lowering 23
BNF 20122,8Standard target 20
Cost for the initial state £per year
Intensive BP lowering 144 Gamma PAST-BP trial, Curtis,
BNF 20129,16,28Standard target 100 Gamma
Costs of acute disease £one-off cost
Stroke 11020 Gamma Youman et al.19
MI 5487 Gamma Palmer et al.20
UA 3292 Gamma Assumed 60% of MI
Costs for long-term (chronic) disease £per year
Stroke 2721 Gamma Youman et al.19
MI 572 Gamma NICE, Lipid
Modification Guidelines18
UA 572 Gamma NICE, Lipid
Modification Guidelines18
MI: myocardial infarction; UA: unstable angina; BP: blood pressure; GP: general practitioner; PN: practice nurse.
aRelative risk comparing blood pressure after treatment with baseline blood pressure.
bThese figures are multiplied by initial health state utility to estimate new health state utility.
cAnnual cost of drugs was calculated on the basis of commonest drug and dose per drug group per arm at 6 and 12 months.
Table 2. Base-case result: lifetime costs and outcomes per patient.
Costs (£) QALYs
Incremental
cost (£)
Incremental
QALYs
ICER
(£per QALY)
Standard target 9889 7.4719
Intensive blood pressure lowering 9720 7.5539 –169 0.082 Dominant
QALY: quality-adjusted life year; ICER: incremental cost-effectiveness ratio.
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Intensive BP lowering was associated with average cost
savings per patient of £169 and an additional 0.08
QALYs over 30 years.
Figure 2 presents the cost-eﬀectiveness plane com-
paring intensive BP lowering to standard target incor-
porating parameter uncertainty. The mean incremental
costs and incremental eﬀects (QALY gains) mostly lie
in the north-east and south-east quadrants, indicating
that intensive BP lowering is highly likely to be eﬀective
but with a large amount of uncertainty around its cost
impact. The CEAC shows that if a decision-maker has
a willingness to pay of £20,000 per QALY gained, the
likelihood of cost eﬀectiveness was 90% (Figure 3).
Sensitivity analysis
Intensive BP lowering was cost eﬀective at £20,000 per
QALY provided at least two years of treatment was
given, and became the dominant strategy after six
years (Supplementary Table 1). Varying costs had
little impact on the overall conclusion, but if the
eﬀect size was reduced to the lower bound of the 95%
-£8,000
-£6,000
-£4,000
-£2,000
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Figure 2. Incremental cost-effectiveness plane comparing the intensive blood pressure lowering strategy with standard target
strategy or usual care.
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Figure 3. Cost-effectiveness acceptability curve for the intensive blood pressure lowering model showing the probability that the
intervention is cost effective.
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conﬁdence interval for BP reduction, intensive targets were
no longer cost eﬀective. If intensive BP lowering is asso-
ciated with a 2% or more reduction in quality of life, it is
no longer eﬀective, but remains the less expensive strategy
because of the reduction in cardiovascular events. In this
circumstance, the incremental cost-eﬀectiveness ratio
(ICER) suggests that standard targets are more cost eﬀect-
ive (Supplementary Table 1).
Discussion
We found that a strategy of intensive BP lowering in
primary care, as tested by the PAST-BP trial, is likely to
be cost eﬀective. The extra initial costs of the intensive
strategy are oﬀset by subsequent cost savings in terms
of reduced cardiovascular events, such that the strategy
is less expensive after six years, although there was
much greater uncertainty around the impact on costs
as compared to the impact on beneﬁts (Figure 2). The
intensive strategy is not cost eﬀective if it is associated
with a 2% or more reduction in quality of life.
However, we have found in a previous trial that reduc-
tions in BP of the order of magnitude seen in PAST-BP
were not associated with any eﬀect on quality of life,24
and there were no signiﬁcant diﬀerences in adverse
eﬀects during the trial.9 This analysis assumes that the
diﬀerence in BP between the arms is maintained over
time: the sensitivity analysis suggested that the ICER
remains below £20,000/QALY provided the time hori-
zon is at least two years. Furthermore, there is evidence
from the SPS3 trial, which involved diﬀerent targets
for BP in people with a history of lacunar stroke, that
diﬀerences between arms were maintained up to eight
years after randomisation.25
PAST-BP was not powered to detect diﬀerences in
cardiovascular events between arms, and so the impact
of observed BP reductions was estimated by applying
these to the results of a systematic literature review.13
Recent evidence reinforces the likelihood that BP
reductions are indeed likely to lead to a reduction in
the risk of cardiovascular events.6 While this evidence
was not restricted to people with previous stroke, the
relative reductions in cardiovascular risk associated
with reduction in BP appear to be similar in people
with and without existing cerebrovascular disease.26
Our results are consistent with the results of a cost-
eﬀectiveness analysis based on the PROGRESS trial,
which found treating people with cerebrovascular dis-
ease was cost eﬀective, with a cost per QALY of £6927
over four years.27 Whereas our analysis found long-term
treatment to be dominant, the PROGRESS trial found
long-term treatment remained more expensive than
standard care. It is likely that this diﬀerence in costs
reﬂects changes in drug prices since the PROGRESS
economic analysis was performed. Our sensitivity
analysis (see Supplementary Table 1) showed that a
30% increase in the initial cost of intensive BP lowering
resulted in the intensive target arm becoming more
expensive than the standard care arm. A change of this
magnitude is plausible given that, for example, perindo-
pril now costs £1.72 per month, as opposed to £10.95, as
applied in 2005.27,28
Strengths and limitations
This study used cost and outcome data from a primary
care based pragmatic randomised controlled trial in
patients with a past history of stroke or TIA.9 The
use of a Markov model overcame limitations associated
with within-trial analyses, speciﬁcally allowing the
modelling of eﬀects and costs on long-term events
and the assessment of the long-term cost eﬀectiveness
beyond the trial period.
The model did not include the recurrence of cardio-
vascular events beyond the ﬁrst event. However, as the
intensive lowering strategy was more eﬀective and there-
fore likely to reduce cardiovascular risk, then this model
simpliﬁcation is likely to have produced more conserva-
tive model results.
Linked to this, an additional limitation derives from
the nature of Markov models. These assume that the
probability of an individual moving to any given health
state in one time period depends only on their current
health state. Therefore a patient’s outcomes and costs
are assumed to depend only on the current health state,
and this may underestimate overall costs and overesti-
mate health outcomes for those who have suﬀered more
than one event. Again, this is likely to have reduced the
apparent cost eﬀectiveness of intensive BP lowering.
The PAST-BP trial did not have a ‘usual care’ arm –
rather it compared two active management strategies,
one to an intensive target, one to a standard target. As
a result, the cost-eﬀectiveness analysis can only com-
pare these two active strategies – it cannot examine the
cost eﬀectiveness of moving from usual care to active
management.
Clinical implications
This analysis suggests that intensive BP lowering in a
post-stroke population in primary care is likely to be
cost eﬀective, despite the relatively small reduction in
SBP with which it is associated. However, comparison
of achieved BP in the control group with less active BP
management suggests that it is also likely that active
management of BP is more important than the target
that is used.9,24 Therefore, it is diﬃcult to determine
from this economic analysis whether the priority should
be to promote systolic targets less than 130mmHg, or to
promote more active management of BP. The overall
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conclusion from this work is that interventions lowering
BP post-stroke are likely to be cost eﬀective provided
that they can be achieved without excessive additional
cost or impact on quality of life. Intensive lowering of
BP in primary care appears to be one such option.
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